Nanoencapsulation improves the protective effects of a nitric oxide donor on drought-stressed Heliocarpus popayanensis seedlings.

Despite the important role played by nitric oxide (NO) in plants subjected to abiotic stress, NO donors application to induce drought tolerance in neotropical tree seedlings has not yet been tested. It is also worth investigating whether NO bioactivity in drought-stressed seedlings could be potentiated by NO donors nanoencapsulation. The aim of the current study is to evaluate the effects of chitosan nanoparticles (NPs) containing S-nitroso-mercaptosuccinic acid (S-nitroso-MSA) on drought-stressed seedlings of neotropical tree species Heliocarpus popayanensis Kunth in comparison to free NO donor and NPs loaded with non-nitrosated MSA. Nanoencapsulation slowed down NO release from S-nitroso-MSA, and nanoencapsulated S-nitroso-MSA yielded 2- and 1.6-fold higher S-nitrosothiol levels in H. popayanensis roots and leaves, respectively, than the free NO donor. S-nitroso-MSA has prevented drought-induced CO2 assimilation inhibition, regardless of nanoencapsulation, but the nanoencapsulated NO donor has induced earlier ameliorative effect. Both NO and MSA have decreased oxidative stress in H. popayanensis roots, but this effect was not associated with antioxidant enzyme induction, with higher seedling biomass, or with proline and glycine betaine accumulation. Nanoencapsulated S-nitroso-MSA was the only formulation capable of increasing leaf relative water content in drought-stressed plants (from 32.3% to 60.5%). In addition, it induced root hair formation (increase by 36.6% in comparison to well-hydrated plants). Overall, results have evidenced that nanoencapsulation was capable of improving the protective effect of S-nitroso-MSA on H. popayanensis seedlings subjected to drought stress, a fact that highlighted the potential application of NO-releasing NPs to obtain drought-tolerant tree seedlings for reforestation programs.

Association of UGT2B7, UGT1A9, ABCG2, and IL23R polymorphisms with rejection risk in kidney transplant patients.

Despite advances in testing compatibility between donor and recipient, graft rejection remains a current concern. Single-nucleotide polymorphisms (SNPs) that codify altered enzymes of metabolism, drug transport, and the immune system may contribute to graft rejection in transplant patients. This study examined the association between SNPs present in genes of these processes and occurrence of graft rejection episodes in 246 kidney transplant patients, 35% of which were diagnosed with rejection. Genotype-gene expression associations were also assessed. Peripheral blood samples were used for genotyping of 24 SNPs on the following genes: CYP3A4, CYP3A5, CYP2E1, POR, UGT2B7, UGT1A9, ABCB1, ABCC2, ABCG2, SLCO1B1, TNF, IL2, IRF5, TGFB1, NFKBIA, IL10, IL23R, NFAT, and CCR5 by real-time PCR. The analysis of gene expression was performed by RT-qPCR. The association between graft rejection episodes and polymorphic variants was assessed using odds ratios. Polymorphisms rs7662029 (UGT2B7) and rs6714486 (UGT1A9) were associated with occurrence of graft rejection episodes, rs7662029 (UGT2B7) exhibited a protective effect (1.85-fold), and rs6714486 (UGT1A9) an increased 1.6-fold increased risk of graft rejection. Among drug transporter genes, only rs2231142 (ABCG2) demonstrated an association with a 1.92-fold decrease in the risk of graft rejection. The immunological SNP rs10889677 (IL23R) was associated with a 1.9-fold enhanced risk of graft rejection. Association between genotypes and gene expression was not detected. Therefore, SNPs of UGT2B7, UGT1A9, ABCG2, and IL23R genes may be useful as candidate markers for screening of risk graft rejection in renal transplant patients. These markers may improve medical decisions, avoiding adverse effects.